GlycoMimetics Inc expected to post a loss of 14 cents a share - Earnings Preview

Crescent Biopharma

01/11/2023 18:33

* GlycoMimetics Inc  GLYC.OQ   GLYC.O  is expected to show
no
change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for GlycoMimetics Inc
is for
a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for
GlycoMimetics Inc
is $5.5​, above​ its last closing price of $1.25. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.18       -0.18      -0.13     Beat    29.1
 Mar. 31 2023  -0.16       -0.17      -0.17     Met     -2
 Dec. 31 2022  -0.17       -0.17      -0.19     Missed  -14​
 Sep. 30 2022  -0.23       -0.26      -0.16     Beat    39.2
 ​​Jun.        -0.29       -0.28      -0.25     Beat    12.3
 30 2022                                                
 Mar. 31 2022  -0.31       -0.31      -0.28     Beat    8.7​
 Dec. 31 2021  -0.39       -0.34      -0.33     Beat    2.2
 Sep. 30 2021  -0.32       -0.32      -0.34     Missed  -7.1
 This summary was machine generated November 1 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated